Literature DB >> 19573298

Human embryonic stem cell models of Huntington disease.

Jonathan C Niclis1, Alan O Trounson, Mirella Dottori, Andrew M Ellisdon, Stephen P Bottomley, Y Verlinsky, David S Cram.   

Abstract

Huntington disease (HD) is an incurable late-onset neurodegenerative disorder caused by a CAG repeat expansion in exon 1 of the HD gene (HTT). The major hallmark of disease pathology is neurodegeneration in the brain. Currently, there are no useful in-vitro human models of HD. Recently, two human embryonic stem cell (hESC) lines carrying partial (CAG(37)) and fully (CAG(51)) penetrant mutant alleles have been derived from affected IVF embryos identified following preimplantation genetic diagnosis (PGD). Fluorescence polymerase chain reaction (F-PCR) and Genescan analysis confirmed the original embryonic HD genotypes. Reverse transcription PCR (RT-PCR) analysis confirmed the expression of mutant transcripts and western blot analysis demonstrated expression of mutant huntingtin protein (HTT). After treatment with noggin, HD hESC formed neurospheres, which could be further differentiated into cells susceptible to neurodegeneration in HD, namely primary neurones and astrocytes. Small pool PCR analysis of neurosphere cells revealed instability of disease-length CAG repeats following differentiation. The presence of active HTT genes, neural differentiation capabilities and evidence of CAG repeat instability indicates these HD hESC lines may serve as valuable in-vitro human models of HD to better understand the mechanisms of neurodegeneration in patients, and for drug screening to identify new therapies for human clinical trials.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19573298     DOI: 10.1016/s1472-6483(10)60053-3

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  29 in total

Review 1.  Induced pluripotent stem cells--opportunities for disease modelling and drug discovery.

Authors:  Marica Grskovic; Ashkan Javaherian; Berta Strulovici; George Q Daley
Journal:  Nat Rev Drug Discov       Date:  2011-11-11       Impact factor: 84.694

2.  Multiple phenotypes in Huntington disease mouse neural stem cells.

Authors:  James J Ritch; Antonio Valencia; Jonathan Alexander; Ellen Sapp; Leah Gatune; Gavin R Sangrey; Saurabh Sinha; Cally M Scherber; Scott Zeitlin; Ghazaleh Sadri-Vakili; Daniel Irimia; Marian Difiglia; Kimberly B Kegel
Journal:  Mol Cell Neurosci       Date:  2012-04-06       Impact factor: 4.314

3.  Vitrified blastocysts from Preimplantation Genetic Diagnosis (PGD) as a source for human Embryonic Stem Cell (hESC) derivation.

Authors:  Begoña Aran; Miquel Sole; Ignasi Rodriguez-Pizà; Mònica Parriego; Yolanda Muñoz; Montserrat Boada; Pere N Barri; Juan Carlos Izpisúa; Anna Veiga
Journal:  J Assist Reprod Genet       Date:  2012-06-27       Impact factor: 3.412

Review 4.  iPSC-based drug screening for Huntington's disease.

Authors:  Ningzhe Zhang; Barbara J Bailus; Karen L Ring; Lisa M Ellerby
Journal:  Brain Res       Date:  2015-09-30       Impact factor: 3.252

5.  Three-dimensional imaging of human stem cells using soft X-ray tomography.

Authors:  J C Niclis; S V Murphy; D Y Parkinson; A Zedan; A H Sathananthan; D S Cram; P Heraud
Journal:  J R Soc Interface       Date:  2015-07-06       Impact factor: 4.118

Review 6.  Eminent Sources of Adult Mesenchymal Stem Cells and Their Therapeutic Imminence.

Authors:  Dannie Macrin; Joel P Joseph; Aruthra Arumugam Pillai; Arikketh Devi
Journal:  Stem Cell Rev Rep       Date:  2017-12       Impact factor: 5.739

Review 7.  Repeat instability as the basis for human diseases and as a potential target for therapy.

Authors:  Arturo López Castel; John D Cleary; Christopher E Pearson
Journal:  Nat Rev Mol Cell Biol       Date:  2010-03       Impact factor: 94.444

Review 8.  Modeling Huntington's disease with induced pluripotent stem cells.

Authors:  Julia A Kaye; Steven Finkbeiner
Journal:  Mol Cell Neurosci       Date:  2013-02-28       Impact factor: 4.314

Review 9.  Pluripotent stem cells models for Huntington's disease: prospects and challenges.

Authors:  Richard L Carter; Anthony W S Chan
Journal:  J Genet Genomics       Date:  2012-05-09       Impact factor: 4.275

10.  Drug discovery in Parkinson's disease-Update and developments in the use of cellular models.

Authors:  Gaia Skibinski; Steven Finkbeiner
Journal:  Int J High Throughput Screen       Date:  2011-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.